08 December 2022
: Case report 
Budesonide with Low-Dose 6-Mercaptopurine as a Possible New Treatment for IgG4-Related Sclerosing Cholangitis and Systemic IgG4-Related Disease: A Case Report
Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Benjamin Peter Michael Gummlich1ABCDEF, Ali Seif Amir Hosseini2BC, Harald Schwörer1ABCDF*DOI: 10.12659/AJCR.938272
Am J Case Rep 2022; 23:e938272
Figure 2. Magnetic resonance cholangiography (MRC) imaging findings. (A) MRC imaging during monotherapy with prednisolone (5 mg/d p. o.) demonstrating relapsed IgG4-SC. MRC findings indicate an occluded common bile duct. Next to this, intrahepatic bile ducts were dilated. (B) MRC during treatment with budesonide (9 mg/d p. o.) and low-dose 6-mercaptopurine (50 mg/d p. o.) demonstrating normal intra- and extrahepatic bile ducts without signs of IgG4-SC about 1 year after emergency cholecystectomy.